Trial record 1 of 113 for:    Short Bowel Syndrome
Previous Study | Return to List | Next Study

A Prospective, Multi-center Registry for Patients With Short Bowel Syndrome

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2014 by NPS Pharmaceuticals
Sponsor:
Information provided by (Responsible Party):
NPS Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT01990040
First received: November 11, 2013
Last updated: September 19, 2014
Last verified: September 2014
  Purpose

This is a global prospective, observational, multi-center registry to evaluate the long-term safety profile for patients with short bowel syndrome (SBS) who are treated with teduglutide in a routine clinical setting. The registry will also evaluate the long-term clinical outcomes in patients with SBS. SBS patients treated and not treated with teduglutide will be enrolled.


Condition
Short Bowel Syndrome

Study Type: Observational [Patient Registry]
Study Design: Time Perspective: Prospective
Target Follow-Up Duration: 10 Years
Official Title: A Prospective, Multi-center Registry for Patients With Short Bowel Syndrome

Resource links provided by NLM:


Further study details as provided by NPS Pharmaceuticals:

Primary Outcome Measures:
  • Occurrence of colorectal cancer in patients with short bowel syndrome who are treated with teduglutide in a routine clinical setting [ Time Frame: At least 10 years ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Occurrence of other malignancy in patients with short bowel syndrome who are treated with teduglutide in a routine clinical setting [ Time Frame: At least 10 years ] [ Designated as safety issue: Yes ]
  • Actual volume change in parenteral support in patients with short bowel syndrome who are treated with teduglutide in a routine clinical setting [ Time Frame: At least 10 years ] [ Designated as safety issue: No ]
  • Occurrence of benign neoplasia of the gastrointestinal tract, hepatobiliary system, and pancreas in patients with short bowel syndrome who are treated with teduglutide in a routine clinical setting [ Time Frame: 10 years ] [ Designated as safety issue: Yes ]
  • Occurrence of colorectal polyps in patients with short bowel syndrome who are treated with teduglutide in a routine clinical setting [ Time Frame: 10 years ] [ Designated as safety issue: Yes ]
  • Occurrence of intestinal obstruction in patients with short bowel syndrome who are treated with teduglutide in a routine clinical setting [ Time Frame: 10 years ] [ Designated as safety issue: Yes ]
  • Occurrence of pancreatic and biliary disease in patients with short bowel syndrome who who are treated with teduglutide in a routine clinical setting [ Time Frame: 10 years ] [ Designated as safety issue: Yes ]
  • Occurrence of heart failure and other manifestations of volume overload in patients with short bowel syndrome who who are treated with teduglutide in a routine clinical setting [ Time Frame: 10 years ] [ Designated as safety issue: Yes ]
  • Occurrence of allergic/hypersensitivity reaction to teduglutide in patients with short bowel syndrome who who are treated with teduglutide in a routine clinical setting [ Time Frame: 10 years ] [ Designated as safety issue: Yes ]
  • Percentage volume change in parenteral support in patients with short bowel syndrome who are treated with teduglutide in a routine clinical setting [ Time Frame: 10 years ] [ Designated as safety issue: No ]
  • Occurrence of other long-term safety outcomes in patients with short bowel syndrome who are treated with teduglutide in a routine clinical setting [ Time Frame: 10 years ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 1310
Study Start Date: June 2014
Estimated Study Completion Date: December 2029
Estimated Primary Completion Date: December 2028 (Final data collection date for primary outcome measure)
Groups/Cohorts
Teduglutide treated
- SBS patients who have been treated with teduglutide
Non-teduglutide treated
- SBS patients who have not been treated with teduglutide

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

This registry is to enroll both male and female patients, of any age, with a diagnosis of SBS.

Criteria

Inclusion Criteria:

  1. Male and female patients, of any age, with a diagnosis of SBS
  2. Signed informed consent and medical records release by the patient or a legally acceptable representative

Exclusion Criteria:

None

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01990040

Contacts
Contact: NPS Clinical Operations 908-450-5300

Locations
United States, Connecticut
Gastroenterology Associates of Fairfield County Recruiting
Bridgeport, Connecticut, United States, 06606
Contact: Janet Kusick    230-333-3328    jkusick@gidox.com   
Principal Investigator: Eddy Castillo, MD         
United States, Florida
Sanitas Research Recruiting
Coral Gables, Florida, United States, 33134
Contact: Ricardo Castaneda    305-441-9700    crc3@sanitas-research.com   
Principal Investigator: Vladimir Santos, MD         
Florida Medical Center and Research Inc Recruiting
Miami, Florida, United States, 33142
Contact: Kathy Ferro       kferro@flmedresearch.com   
Principal Investigator: Ramon Berenguer, MD         
United States, Massachusetts
Tufts Medical Center Recruiting
Boston, Massachusetts, United States, 02111
Contact: Joel Mason, MD    617-556-3234      
Principal Investigator: Joel Mason, MD         
United States, Michigan
Henry Ford Health System Recruiting
Detroit, Michigan, United States, 48202
Contact: Joanne Dupuis    313-916-1950    jdupuis3@hfhs.org   
Principal Investigator: Maria Segovia, MD         
United States, New Jersey
The Gastroenterology Group of South Jersey Recruiting
Vineland, New Jersey, United States, 08360
Contact: Allison Sacco    856-691-1400    asacco84@yahoo.com   
Principal Investigator: Gary Matusow, MD         
United States, North Carolina
University of North Carolina at Chapel Hill - Department of Family Medicine Recruiting
Chapel Hill, North Carolina, United States, 27599
Contact: Miriam Perez    919-843-5795    miriamp@med.unc.edu   
Principal Investigator: Millie Long, MD         
United States, Oregon
Northwest Gastroenterology Clinic, LLC Recruiting
Portland, Oregon, United States, 97210
Contact: Melissa Keaton    503-229-7181    mkeaton@nwgastro.net   
Principal Investigator: Roland Bennetts, MD         
United States, Texas
Gastroenterology Research of San Antonio, LLC Recruiting
San Antonio, Texas, United States, 78229
Contact: Kathy Untermeyer    210-615-3848    gersama@gastroclinicsa.com   
Principal Investigator: David Stump, MD         
United States, Wisconsin
Digestive Health Center Recruiting
Madison, Wisconsin, United States, 53705
Contact: Jill Surfus    608-263-4185    jcsurfus@medicine.wisc.edu   
Principal Investigator: Mark Reichelderfer, MD         
Sponsors and Collaborators
NPS Pharmaceuticals
  More Information

No publications provided

Responsible Party: NPS Pharmaceuticals
ClinicalTrials.gov Identifier: NCT01990040     History of Changes
Other Study ID Numbers: TED-R13-002
Study First Received: November 11, 2013
Last Updated: September 19, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by NPS Pharmaceuticals:
Short Bowel Syndrome
SBS
teduglutide
Gattex

Additional relevant MeSH terms:
Short Bowel Syndrome
Syndrome
Digestive System Diseases
Disease
Gastrointestinal Diseases
Intestinal Diseases
Malabsorption Syndromes
Pathologic Processes
Postoperative Complications

ClinicalTrials.gov processed this record on October 23, 2014